Early Onset Parkinson's Disease CLG

Directors' Report and Unaudited Financial Statements

for the financial year ended 31 December 2024

Dillon Kelly Cregan
Chartered Certified Accountants
18 Upper Mount Street
Dublin 2
D02 ER26

Company Number: 684095

Early Onset Parkinson's Disease CLG
CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Accountants' Report	7
Income and Expenditure Account	8
Balance Sheet	9
Statement of Changes in Equity	10
Statement of Cash Flows	11
Notes to the Financial Statements	12 - 13
Supplementary Information on Trading Statement	15 - 16

Early Onset Parkinson's Disease CLG
DIRECTORS AND OTHER INFORMATION

Directors	Joseph Condon John Kernan Fiona Staunton Evin Conway (Appointed 5 July 2024) Ciarán Bolger Kieran Fallon Michelle Todman (Appointed 25 April 2024) Freda Cunningham (Appointed 21 May 2024, Resigned 9 June 2025) Lucia Power (Resigned 26 March 2024) David Bradley (Resigned 4 July 2024)
Company Secretary	Joseph Condon
Company Number	684095
Registered Office and Business Address	77 Lower Camden Street Dublin 2 D02XE80
Accountants	Dillon Kelly Cregan Chartered Certified Accountants 18 Upper Mount Street Dublin 2 D02 ER26
Bankers	Bank of Ireland 33/34 Arran Quay Smithfield Dublin 7
Solicitors	Eugene F Collins Temple Chambers 3 Burlington Road Dublin 4 D04 RD68

Early Onset Parkinson's Disease CLG
DIRECTORS' REPORT
for the financial year ended 31 December 2024

The directors present their report and the unaudited financial statements for the financial year ended 31 December 2024.

Principal Activity and Review of the Business
The principal activities are to provide information, organise events and exercise classes which also allow people to connect for peer support. Advocate and work with researchers to help enhance the lives of people living with Parkinson's and in particular Early onset Parkinson's disease

Registered Charity Number (RCN): 20206267.

The Company is limited by guarantee not having a share capital.

There has been no significant change in these activities during the financial year ended 31 December 2024.

Financial Results
The surplus for the financial year amounted to €1,199 (2023 - €76,682).

At the end of the financial year, the company has assets of €102,056 (2023 - €109,584) and liabilities of €2,960 (2023 - €11,687). The net assets of the company have increased by €1,199.

Directors and Secretary
The directors who served throughout the financial year, except as noted, were as follows:

Joseph Condon
John Kernan
Fiona Staunton
Evin Conway (Appointed 5 July 2024)
Ciarán Bolger
Kieran Fallon
Michelle Todman (Appointed 25 April 2024)
Freda Cunningham (Appointed 21 May 2024, Resigned 9 June 2025)
Lucia Power (Resigned 26 March 2024)
David Bradley (Resigned 4 July 2024)

The secretary who served throughout the financial year was Joseph Condon.

Future Developments
The company plans to continue its present activities.

Post Balance Sheet Events
There have been no significant events affecting the company since the financial year-end.

Preparation of financial statements
The financial statements are prepared using the accounting standard FRS 102. The company has not used the Charities SORP.

Accounting Records
To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at 77 Lower Camden Street, Dublin 2, D02XE80.

Signed on behalf of the board

Joseph Condon
Director

John Kernan
Director

29 July 2025

Early Onset Parkinson's Disease CLG
DIRECTORS' RESPONSIBILITIES STATEMENT
for the financial year ended 31 December 2024

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:
- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Joseph Condon
Director

John Kernan
Director

29 July 2025

Early Onset Parkinson's Disease CLG

CHARTERED CERTIFIED ACCOUNTANTS REPORT

to the Board of Directors on the Compilation of the unaudited financial statements of Early Onset Parkinson's Disease CLG for the financial year ended 31 December 2024

In accordance with our engagement letter and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled for your approval the financial statements of the company for the financial year ended 31 December 2024 as set out on pages 8 to 13 which comprise the Income and Expenditure Account, the Balance Sheet, the Statement of Changes in Equity, the Statement of Cash Flows and the related notes from the company's accounting records and from information and explanations you have given to us.

This report is made solely to the Board of Directors of Early Onset Parkinson's Disease CLG, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's Board of Directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and its Board of Directors, as a body, for our work or for this report.

We have carried out this engagement in accordance with guidance issued by Association of Chartered Certified Accountants and have complied with the relevant ethical guidance laid down by Association of Chartered Certified Accountants relating to members undertaking the compilation of financial statements.

You have acknowledged on the Balance Sheet for the year ended 31 December 2024 your duty to ensure that Early Onset Parkinson's Disease CLG has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and surplus of Early Onset Parkinson's Disease CLG. You consider that Early Onset Parkinson's Disease CLG is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the financial statements of Early Onset Parkinson's Disease CLG. For this reason, we have not verified the adequacy, accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

DILLON KELLY CREGAN
Chartered Certified Accountants
18 Upper Mount Street
Dublin 2
D02 ER26

29 July 2025

Early Onset Parkinson's Disease CLG
INCOME AND EXPENDITURE ACCOUNT
for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Income		**31,274**	118,157
Expenditure		**(30,075)**	(41,475)
Surplus before tax		**1,199**	76,682
Tax on surplus		**-**	-
Surplus for the financial year		**1,199**	76,682
Total comprehensive income		**1,199**	76,682

Approved by the board on 29 July 2025 and signed on its behalf by:

Joseph Condon
Director

John Kernan
Director

Early Onset Parkinson's Disease CLG
BALANCE SHEET
as at 31 December 2024

	Notes	2024 €	2023 €
Current Assets			
Debtors	**5**	**982**	1,449
Cash and cash equivalents		**101,074**	108,135
		102,056	109,584
Creditors: amounts falling due within one year	**7**	**(2,960)**	(11,687)
Net Current Assets		**99,096**	97,897
Total Assets less Current Liabilities		**99,096**	97,897
Reserves			
Income and expenditure account		**99,096**	97,897
Equity attributable to owners of the company		**99,096**	97,897

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Early Onset Parkinson's Disease CLG, state that -
(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the members of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company.

Approved by the board on 29 July 2025 and signed on its behalf by:

Joseph Condon
Director

John Kernan
Director

Early Onset Parkinson's Disease CLG
STATEMENT OF CHANGES IN EQUITY
as at 31 December 2024

	Retained surplus	Total
	€	€
At 1 January 2023	21,215	21,215
Surplus for the financial year	76,682	76,682
At 31 December 2023	97,897	97,897
Surplus for the financial year	1,199	1,199
At 31 December 2024	**99,096**	**99,096**

Early Onset Parkinson's Disease CLG
STATEMENT OF CASH FLOWS
for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Cash flows from operating activities			
Surplus for the financial year		**1,199**	76,682
		1,199	76,682
Movements in working capital:			
Movement in debtors		**467**	217
Movement in creditors		**(8,727)**	4,647
Cash (used in)/generated from operations		**(7,061)**	81,546
Net (decrease)/increase in cash and cash equivalents		**(7,061)**	81,546
Cash and cash equivalents at beginning of financial year		**108,135**	26,589
Cash and cash equivalents at end of financial year	**6**	**101,074**	108,135

1. General Information

Early Onset Parkinson's Disease CLG is a company limited by guarantee incorporated and registered in Ireland. The registered number of the company is 684095. The registered office of the company is 77 Lower Camden Street, Dublin 2, D02XE80 which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance
The financial statements of the company for the financial year ended 31 December 2024 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the ‘Small Companies Regime’ in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income
Income is recognised when the company has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measures reliably.

Grants from Government and other institutional donors: where related to performance and specific deliverables are accounted for as the company earns the right to consideration by its performance. Where income is received in advance it is deferred and included in creditors. Where entitlement occurs before income being received the income is accrued. Where no performance and specific deliverables are imposed the income is recognised when the company is entitled to the income, it is probable that the company will receive the funds and the amount can be measures reliably.

Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation
No charge to taxation arises as the company is exempt under section 207 and 208 of the Taxes Consolidation Act 1997. The company's charity number is CHY22875.

Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income and Expenditure Account.

Early Onset Parkinson's Disease CLG
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2024

3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. Employees

There was one part time employee during the accounting period.

	2024 Number	2023 Number
Administration	**1**	1

5. Debtors

	2024 €	2023 €
Prepayments	**982**	1,449

6. Cash and cash equivalents

	2024 €	2023 €
Cash and bank balances	**101,074**	108,135

7. Creditors

Amounts falling due within one year	**2024 €**	2023 €
Trade creditors	**-**	4,423
Directors' current accounts	**-**	6,000
Accruals	**2,960**	1,264
	2,960	11,687

8. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one financial year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 1.

9. Capital commitments

The company had no material capital commitments at the financial year-ended 31 December 2024.

10. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

11. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 29 July 2025.

EARLY ONSET PARKINSON'S DISEASE CLG

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

Early Onset Parkinson's Disease CLG
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
TRADING STATEMENT
for the financial year ended 31 December 2024

	Schedule	2024 €	2023 €
Income			
Donations		**29,424**	111,078
General Income		**-**	4,879
Membership		**1,850**	2,200
		31,274	118,157
Overhead expenses	**1**	**(30,075)**	(41,475)
Net surplus		**1,199**	76,682

Early Onset Parkinson's Disease CLG
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
SCHEDULE 1 : OVERHEAD EXPENSES
for the financial year ended 31 December 2024

	2024	2023
	€	€
Administration Expenses		
Wages and salaries	**16,969**	4,559
Training	**6,752**	11,353
Rent payable	**701**	246
Insurance	**1,249**	1,090
Printing, postage and stationery	**263**	214
Advertising	**466**	2,047
Telephone	**205**	628
Computer costs	**1,037**	18,817
Legal and professional	**40**	23
Accountancy	**1,230**	1,229
Bank charges	**352**	455
General expenses	**-**	24
Subscriptions	**811**	790
	30,075	41,475